The results of the present analyses are consistent with findings of a phase 2 trial with semaglutide at doses up to 0.4 mg/day (equivalent to 2.8 mg/week) in adults with obesity and without type 2 diabetes, which demonstrated significant, broadly dose-dependent reductions of CRP with semaglutide compared with placebo.21 The gene discussed is CRP; the disease is Obesity.